Treatment of post-partum haemorrhage with sublingual misoprostol versus oxytocin in women receiving prophylactic oxytocin: a double-blind, randomised, non-inferiority trial

Blum J., Winikoff B., Raghavan S., Dabash R., Ramadan M. C., Dilbaz B., ...More

LANCET, vol.375, no.9710, pp.217-223, 2010 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 375 Issue: 9710
  • Publication Date: 2010
  • Doi Number: 10.1016/s0140-6736(09)61923-1
  • Journal Name: LANCET
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.217-223
  • Yozgat Bozok University Affiliated: No


Background Oxytocin, the gold-standard treatment for post-partum haemorrhage, needs refrigeration, intravenous infusion, and skilled providers for optimum use. Misoprostol, a potential alternative, is increasingly used ad hoc for treatment of post-partum haemorrhage; however, evidence is insufficient to lend support to recommendations for its use. This trial established whether sublingual misoprostol is non-inferior to intravenous oxytocin for treatment of post-partum haemorrhage in women receiving prophylactic oxytocin.